Chylomicron remnant particle

Chylomicron remnant particles are the metabolic byproducts resulting from the lipolysis of dietary chylomicrons, which are large triglyceride-rich lipoproteins produced by enterocytes following fat consumption[2][8]. These remnants are smaller, cholesterol-enriched lipoprotein particles that carry a high concentration of cholesterol, often more per particle than LDL, and are recognized as particularly atherogenic[1][10]. Their core structural protein is apolipoprotein B-48, with additional surface apolipoproteins such as ApoE, which mediate hepatic uptake via LDL receptor-related pathways[8][9]. In health, they deliver dietary lipid cargo to the liver, but when overproduced or improperly cleared, they contribute to plaque formation via accumulation in the arterial wall, foam cell formation, and enhanced inflammatory responses[1][4][5][7]. Current cardiovascular risk stratification includes remnant cholesterol (total cholesterol minus LDL-C and HDL-C) as an emerging important biomarker for atherosclerotic cardiovascular disease[4]. Direct pharmacological targeting of chylomicron remnant particles is not established; instead, therapeutic approaches focus on modulating triglyceride and cholesterol metabolism using lipid-lowering agents (such as statins and fibrates)[3][6]. As such, "chylomicron remnant particle" is not a classical druggable molecular target (such as a receptor, enzyme, or transporter), but an important pathophysiological entity and biomarker in cardiovascular disease.

Other names

Chylomicron remnantChylomicron remnant lipoproteinCMR